Danaher Event

2022 Danaher Summit: Genomes to Cures

12.07.22 - 12.08.22 EDT

United States

Scientist examining DNA (deoxyribonucleic acid) results on a screen during an experiment in the laboratory.

On December 7, 2022 in Boston, we held the first Danaher Summit, themed Genomes to Cures™. 

About the event

This new annual forum for industry and academic leaders aimed to examine and debate the challenges and opportunities in the evolution of new genome-based modalities, with a call to action for specific collaborative efforts. The invitation-only event addressed a spectrum of topics related to the future of genomic medicines. World-renowned scientists, researchers and industry leaders gathered to explore key scientific innovations essential to enabling the identification, validation, manufacturing and rapid development of these advanced therapeutics.

The Summit was attended by world-leading experts in the field of genomic medicines, from Nobel-laureate researchers and top academic opinion leaders to biopharma CEOs, biotech entrepreneurs, investor groups and next-generation biomanufacturing companies. We convened these pioneers at a critical time for the biopharma and life sciences industries—a time when the emerging field of genomic medicine is radically transforming the treatment of disease as it evolves from responses to long-term remissions and cures.

Summit Sessions

Screenshot of Genomics in the post-genome era YouTube talk

Genomics in the Post-Genome Era

Dr. Siddhartha Mukherjee M.D. DPhil, Department of Medicine, Columbia University

 

An overview of the past, present and future of genomic medicines and discuss the societal and ethical obligations for global democratization of these potentially curative therapies.

Screenshot of Convergent Innovation in Genomic Medicines YouTube talk

Convergent Innovation in Genomic Medicines

George Church, Ph.D.

 

“Convergence” involves combining technological and social innovation in ways that guide divergent, out-of-the-box ideas into daily life. Ideally, this convergence will create solutions that improve health care, while reducing costs and social inequities. The future of medicine promises to bring more convergent innovations that will revolutionize health care.

Screenshot of Catapulting Innovation YouTube talk

Catapulting Innovation

Andrew W. Lo

 

We’re experiencing a Golden Age of Biomedicine, but the funding and business models we use to commercialize these technologies have barely changed, making it challenging for younger scientists and entrepreneurs to bring their most innovative ideas into practice. Professor Lo describes the financial considerations that create bottlenecks in commercialization, delivery and reimbursement, as well as current and emerging solutions, including venture philanthropy, portfolio companies, securitization techniques and new payment models.

Screenshot of The Great Acceleration Panel YouTube talk

The Great Acceleration Panel

Moderated by Conor McKechnie

 

Panelists:
Mitchell Finer, ElevateBio  
Doug Ingram, Sarepta 
Eliana Clark, Intellia 
Katy Rezvani, MD Anderson Cancer Center 
Sonia Vallabh, Mass General Hospital, Broad Institute

 

This panel covers the current challenges that drug developers  face in advancing potential life-saving treatments to patients, with specific focus on biomanufacturing and regulatory guidance. Panelists  also discuss opportunities to change the paradigm of drug development and to implement sustainable manufacturing of genomic medicines.

Screenshot of A Visionary View on the Future Panel YouTube talk

A Visionary View on the Future Panel

Moderated by JC Gutierrez-Ramos

 

Panelists: 
Carl June, University of Pennsylvania 
George Church, Harvard Medical School 
Fyodor Urnov, Innovative Genomic Institute, Berkeley University 
Peter Marks, CBER at the FDA

 

Panelists provide their perspectives on the programs and the platforms that have the biggest potential to provide therapeutic benefits, with line of sight for smooth regulatory pathways. We discuss a future of highly personalized therapeutics, its implications, and the role and responsibilities for all involved parties—and, importantly, opportunities for new regulatory frameworks to enable this new wave of therapeutic advances.

More from Danaher